AlzeCure drug presents opportunity to treat Alzheimer’s disease
Pf Media Magazine
by Joanna Harvey
3d ago
AlzeCure, a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer’s disease and pain, has received preclinical data for NeuroRestore in inflammation, presenting an opportunity to treat Alzheimer’s disease, which is being prepared for phase II clinical studies. The data shows that the NeuroRestore substance ACD856 exhibits anti-inflammatory properties both centrally in the brain and peripherally in the body, with relief of clinical inflammatory symptoms in preclinical models and a reduction in several inflammatory markers. These ne ..read more
Visit website
Genetic link between inflammatory bowel disease and Parkinson’s disease
Pf Media Magazine
by Joanna Harvey
3d ago
A genetic link between inflammatory bowel disease (IBD) and Parkinson’s disease (PD) has been identified by researchers at the Icahn School of Medicine, Mount Sinai. The team used advanced genomic analysis techniques to investigate the genetic overlap between IBD and PD, with their findings pointing to mutations in the LRRK2 gene as a common element linking both conditions, also identifying novel genes that are likely to be affected in people experiencing both IBD and PD. The study analysed data from the Mount Sinai BioMe BioBank, the UK Biobank, and a cohort of 67 patients diagnosed with both ..read more
Visit website
NICE recommends first treatment for rare heart condition
Pf Media Magazine
by Joanna Harvey
3d ago
The National Institute for Health and Care Excellence (NICE) has published final draft guidance which recommends Vyndaqel®▼ (tafamidis) for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM)1 to be routinely available on the NHS. The NICE final draft guidance is subject to appeal, with final guidance anticipated in June. However, from today, patients in England will be able to access tafamidis via interim funding through the Innovative Medicines Fund (IMF), until it becomes routinely available on the NHS. ATTR-CM is an underd ..read more
Visit website
Dare to be disruptive – how to model your European go to market strategy for success 
Pf Media Magazine
by Nick Bartlett
5d ago
Refreshed and re-energised after returning from Reuters Pharma 2024 in Barcelona, Nick Bartlett, Head of Consulting at Uniphar, brings you key takeaways from the workshop he led about shaking up disruption in pharma, European go to market models and embracing change.   The Uniphar team joined over 1200 industry leaders to discuss innovation in healthcare and tackle some of the new (and old) problems that are holding back engagement with healthcare professionals.  Whilst there, we shared our expertise encouraging attendees to Embrace disruption now to successfully model your G2M ..read more
Visit website
Positive results from head and neck cancer trial
Pf Media Magazine
by Joanna Harvey
1w ago
Calliditas Therapeutics have confirmed positive data from the proof-of-concept Phase 2 trial, in patients with head and neck cancer. The trial evaluated setanaxib, its lead NOX enzyme inhibitor, in combination with pembrolizumab, in patients with squamous cell carcinoma of the head and neck (SCCHN). The analysis showed statistically significant improvements in progression-free survival (PFS), as well as in overall survival (OS), with statistically significant changes in tumour biology consistent with the mechanism of action of setanaxib. The trial is a randomised, placebo-controlled, double-bl ..read more
Visit website
Immune cells discovery could lead to personalised breast cancer treatments
Pf Media Magazine
by Joanna Harvey
1w ago
The discovery of key features of immune B cells, which make them successful at targeting tumours – including when cancer has spread to a different part of the body – could lead to improved, personalised immunotherapies and treatments for advanced breast cancer. Most immunotherapies only work for a minority of patients, and researchers are urgently working to expand the group of patients who could benefit from them. Scientists at The Institute of Cancer Research (ICR) took biopsies from patients with breast cancer and used a technique called B cell receptor sequencing to identify genetic variat ..read more
Visit website
NHS rolls out ‘life-changing’ treatment for sickle cell disease
Pf Media Magazine
by Joanna Harvey
1w ago
Thousands of patients with sickle cell disease are to be offered a new ‘life-changing’ treatment on the NHS, following the approval and roll-out of a new drug, Oxbryta®▼ (voxelotor), that could significantly improve their quality of life. Up to 4,000 people with sickle cell disease in England could benefit from the drug if recommended by their clinician, following its approval by the National Institute for Health and Care Excellence (NICE). Voxelotor will be used to treat sickle cell anaemia in people aged 12 and older and it will be administered in the form of a tablet, taken once a day for e ..read more
Visit website
Prescribing pharmacists; a game-changer in the UK healthcare market
Pf Media Magazine
by Kate Kelly
2w ago
The healthcare delivery landscape in the UK is transforming with the rise of prescribing pharmacists. Pharmacists have seen an evolvement with their role in the last decade with respect to supporting patients, NHS initiatives, and creating quicker access to care. We are now seeing them play an increasingly active part in patient care, obtaining prescribing rights, and advising on vital preventative medicine routes. All over the UK, demand for accessible and cost-effective healthcare services continues to rise, with resources stretched as we recover from the pandemic and the knock-on effect it ..read more
Visit website
Europe’s decisive role in global healthcare’s future
Pf Media Magazine
by Joanna Harvey
2w ago
As we look ahead to 2028, a confluence of factors will position Europe to play a decisive role in shaping the future of global healthcare. From policy leadership to research and development prowess, Europe’s impact will be felt across many dimensions. Policy and regulatory harmonisation One of the key drivers will be Europe’s continued push for harmonisation of healthcare policies and regulations across the EU member states. Initiatives like the European Health Data Space aim to create a single market for digital health services and products by 2028. This will facilitate cross-border healthcar ..read more
Visit website
ABPI respond to proposals to change the Statutory Scheme
Pf Media Magazine
by Emma Cooper
2w ago
The Association of the British Pharmaceutical Industry (ABPI) has published an executive summary1 of its consultation response to the government’s proposed changes to the Statutory Scheme for branded medicines2. In its response, the ABPI acknowledged and broadly supported the government’s intention to bring the Statutory Scheme into alignment with the new Voluntary Scheme for Pricing Access and Growth (VPAG), which was agreed with the industry at the end of last year. However, the industry also expressed reservations about many of the specific proposals in the consultation, some of which remai ..read more
Visit website

Follow Pf Media Magazine on FeedSpot

Continue with Google
Continue with Apple
OR